At the end of the latest market close, Aprea Therapeutics Inc. (APRE) was valued at $8.15. In that particular session, Stock kicked-off at the price of $8.45 while reaching the peak value of $8.46 and lowest value recorded on the day was $7.33. The stock current value is $7.35.
Recently in News on January 8, 2021, Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, will present a corporate update at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. ET. You can read further details here
Aprea Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $8.46 on 02/11/21, with the lowest value was $4.66 for the same time period, recorded on 01/04/21.
Aprea Therapeutics Inc. (APRE) full year performance was -78.71%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Aprea Therapeutics Inc. shares are logging -82.12% during the 52-week period from high price, and 57.72% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $4.66 and $41.12.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3571956 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Aprea Therapeutics Inc. (APRE) recorded performance in the market was 49.39%, having the revenues showcasing -66.13% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 149.43M, as it employees total of 13 workers.
Specialists analysis on Aprea Therapeutics Inc. (APRE)
During the last month, 0 analysts gave the Aprea Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 18.72, with a change in the price was noted -22.21. In a similar fashion, Aprea Therapeutics Inc. posted a movement of -75.14% for the period of last 100 days, recording 1,032,515 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for APRE is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Aprea Therapeutics Inc. (APRE)
Raw Stochastic average of Aprea Therapeutics Inc. in the period of last 50 days is set at 10.22%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 67.35%. In the last 20 days, the company’s Stochastic %K was 82.95% and its Stochastic %D was recorded 81.84%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 49.39%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -73.89%, alongside a downfall of -78.71% for the period of the last 12 months. The shares increased approximately by 15.20% in the 7-day charts and went down by 43.27% in the period of the last 30 days. Common stock shares were lifted by -66.13% during last recorded quarter.